WAYNE, Pa., May 21, 2026
Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of the Year at the prestigious 2026 Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards, recognizing the company’s innovation, clinical progress, and growing leadership in the rare disease biotechnology sector. The award highlights Palvella’s rapid advancement in developing novel therapies for patients suffering from serious rare skin diseases and vascular malformations, conditions for which there are currently no FDA-approved treatments available.
PACT Recognizes Palvella’s Clinical and Business Momentum
The annual PACT Ecosystem Awards celebrate leading healthcare, life sciences, and technology companies that are driving innovation and economic growth across the Greater Philadelphia region. Companies are evaluated based on several factors, including development of innovative therapies, advancement of clinical programs, business execution, capital formation, and potential impact on patient care.
Palvella Therapeutics was selected for its strong pipeline of proprietary therapies and its continued progress in advancing treatments for underserved rare disease patient populations. The company’s recognition reflects growing industry attention on its novel QTORIN™ platform technology, which is designed to address severe dermatological and vascular disorders with limited or no treatment options.
Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics, stated that the award recognizes the dedication and execution of the entire Palvella team as the company works to develop meaningful therapies for patients facing lifelong and debilitating rare conditions. He also highlighted the importance of the Greater Philadelphia life sciences ecosystem in supporting innovation and biotech growth.
QTORIN Platform Drives Rare Disease Pipeline Expansion
Advertisement
Palvella Therapeutics is currently developing multiple investigational therapies based on its proprietary QTORIN™ platform, with an initial focus on rare skin diseases and vascular malformations. The company’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being evaluated for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas.
These conditions are often chronic, progressive, and associated with severe pain, bleeding, infections, cosmetic disfigurement, and reduced quality of life. Despite the serious burden on patients, there are currently no FDA-approved therapies specifically indicated for many of these disorders, creating a significant unmet medical need.
In addition to QTORIN™ rapamycin, the company is also advancing QTORIN™ pitavastatin, which is under development for the treatment of disseminated superficial actinic porokeratosis (DSAP), a rare skin disorder associated with abnormal keratinization and elevated skin cancer risk.
Palvella’s growing pipeline positions the company as an emerging player in the rare dermatology and vascular anomaly treatment market, an area that continues attracting significant investor and clinical interest due to limited competition and high unmet need.
Rare Disease Biotech Sector Continues to Grow
The recognition from PACT comes as the rare disease biotechnology sector experiences increasing momentum, with investors and regulators showing stronger support for companies developing therapies targeting underserved patient populations. Palvella’s progress in both clinical development and strategic execution has helped establish the company as one of the more closely watched clinical-stage rare disease biopharma companies in the region.
The company noted that both QTORIN™ rapamycin and QTORIN™ pitavastatin remain investigational therapies and have not yet received approval from the U.S. Food and Drug Administration or any other regulatory agency.
Palvella was founded and is led by experienced rare disease biotechnology executives and continues to expand its development programs focused on diseases with limited therapeutic options. Industry observers believe the company’s differentiated topical delivery platform and focus on orphan dermatology indications may provide important long-term commercial opportunities if future clinical studies continue to demonstrate positive efficacy and safety outcomes.
The PACT award further reinforces Palvella’s growing visibility within the biotechnology sector as it advances multiple rare disease treatment candidates toward later-stage clinical development and potential future regulatory submissions.
Source: Palvella Therapeutics press release
